London, 28 September 2022 — Novartis Pharmaceuticals UK has today announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+.

Lifelight and PocDoc will receive support to scale their innovative digital solutions for cardiovascular disease (CVD) care. The companies were selected by a prestigious judging panel at the Novartis Biome UK Heart Health Catalyst 2022 Pitchfest, hosted at the Healthcare Excellence Through Technology (HETT) Show at ExCeL, London.

Through a world-first partnership spanning across industries, the Novartis Biome UK Heart Health Catalyst aims to transform CVD patient pathways, harnessing the power of data and digital to empower patients to improve their heart health, and to help prevent ill-health.

The initiative provides Lifelight and PocDoc with access to the Novartis Biome UK eco-system, as well as the opportunity to work with NHS partners to set up and deliver a pilot evaluation of the winning innovations. The companies will also have the opportunity of investment up to £3 million provided by RYSE Asset Management, subject to due diligence at RYSE’s discretion.

The companies have been selected because of their potential to remodel patient care pathways for CVD; offering novel approaches to non-invasive lipid testing and at-home blood pressure management.

Marie-Andrée Gamache, President and Managing Director UK & Ireland, Novartis P…